Treatment of Hypertension in a Child With 11Beta-Hydroxylase Deficiency: A Case Report
Author(s) -
Fatemeh Saffari,
Banafsheh Arad
Publication year - 2022
Publication title -
journal of pediatrics review
Language(s) - English
Resource type - Journals
eISSN - 2322-4401
pISSN - 2322-4398
DOI - 10.32598/jpr.10.1.993.1
Subject(s) - hypokalemia , medicine , spironolactone , virilization , mineralocorticoid , endocrinology , mineralocorticoid receptor , steroid 11 beta hydroxylase , 21 hydroxylase , blood pressure , secondary hypertension , aldosterone , congenital adrenal hyperplasia , essential hypertension , pediatrics , hormone , androgen , steroid
Deficiency of 11-hydroxylase is clinically presented by external genitalia virilization in girls and precocious puberty in boys. Low renin hypertension occurs in both sexes. Early diagnosis and treatment of hypertension can prevent complications. Case presentation: We described a 4.5 years old girl of 46.XX, who presented with ambiguous genitalia at birth and hypertension later in follow-up. The patient had received the appropriate dosage of hydrocortisone and the level of 17-hydroxy progesterone was within the acceptable range but the hypokalemia persisted. Both hypertension and hypokalemia were normalized when spironolactone was added. Conclusion: Intermittent measurement of blood pressure is necessary for patients with 11β hydroxylase deficiency. In these patients, spironolactone is effective in treating mineralocorticoid-mediated hypertension and hypokalemia by blocking mineralocorticoid receptor.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom